We previously reported a high incidence of loss of heterozygosity (LOH) on chromosome 2q33 in neuroblastoma (NB), observed in various types of human cancers including lung cancer, head and neck cancer and follicular thyroid carcinoma. To better elucidate the role of chromosome 2q aberrations in NB, we examined common allelic imbalance (AI) regions on chromosome 2q in 82 NB patients using 10 polymorphic microsatellite markers. AI on 2q was detected in 26 (32%) of 82 NB cases. There was a distinct common AI region between the D2S115 and D2S307 markers on 2q33. The distance between these markers was about 2.0 cM. Recently, the caspase 8 and caspase 10 genes, both of which encode cystein protease, were mapped to chromosome 2q33. Since the common AI region on 2q33 includes the caspase 8 and caspase 10 genes, the alterations of these genes were examined further. Absent or reduced expression of caspase 8 and caspase 10 were found in 19 (70%) of 27 and two (7%) of 27 NB cell lines by reverse transcription-polymerase chain reaction, respectively. A missense mutation was detected at codon 96, GCT (Alanine) to GTT (Valine), of the caspase 8 gene in one of the NB cell lines lacking caspase 8 expression. Thirteen (68%) of 19 cell lines lacking caspase 8 expression displayed methylation of the CpG island of the caspase 8 gene, whereas only one (13%) of eight cell lines with caspase 8 expression showed caspase 8 methylation (P=0.031). Furthermore, there was a signi®cant association between AI at 2q33 and loss of caspase 8 expression (P=0.026). These results indicated that there was a tumor suppressor gene in the common AI region on chromosome 2q33 involved in the pathogenesis of a subset of NB. It is possible that the caspase 8 gene is one of the candidate tumor suppressor genes for NB and inactivation of this gene plays an important role in the tumorigenesis of NB through mainly its methylation. Oncogene (2001) 20, 4424 ± 4432.
Introduction
Molecular genetic studies in a variety of human cancers indicate that inactivation of multiple tumor suppressor genes is required for tumor development and/or progression (Stanbridge, 1990; Yokota et al., 1993) . Genetically, the loss of a gene or its function can occur through biallelic inactivation (Stanbridge, 1990; Yokota and Sugimura, 1993) . One mode of biallelic inactivation involves the mutation of one allele together with the loss of the second allele. The second mechanism for biallelic inactivation is a homozygous deletion (Stanbridge, 1990; Yokota and Sugimura, 1993) . Furthermore, it was also demonstrated that abnormal DNA methylation is one of the mechanisms for inactivation of the target gene in several types of human cancer (Merlo et al., 1995; Herman et al., 1996; Kawano et al., 1999) .
Neuroblastoma (NB) is a common malignant tumor of childhood originating from embryonal neural crest tissue (Schor, 1999) . Since NB has variable clinical and biological features, it is thought to be a heterogeneous disease, and it is suggested that multiple genetic alterations are involved in the genesis and/or progression of NB (Maris and Matthy, 1999) . The best-known genetic alteration in NB includes ampli®cation of the MYCN oncogene and loss of heterozygosity (LOH) of chromosome 1p (Brodeur et al., 1984; Fong et al., 1989; Schwab, 1993 Schwab, , 1996 . However, since MYCN ampli®cation and 1p LOH occur in approximately one half of all cases of advanced NB, it has been suggested that other genetic events are involved in the genesis and/or progression of NB (Schwab, 1993; Maris and Matthy, 1999) . Previously, we reported that chromosomes 2q, 9p and 18q in addition to 1p, 11q and 14q were frequently deleted in NB as detected by allelotype analysis (Takita et al., 1995) . Furthermore, we also reported that the p16 gene on chromosome 9p21 and the DCC gene on chromosome 18q21 might be candidate tumor suppressor genes inactivated in NB (Kong et al., 1997a,b; Takita et al., 1997 Takita et al., , 1998 Takita et al., , 2000 .
However, the pathogenetic signi®cance of LOH on chromosome 2q in NB and a candidate tumor suppressor gene for NB residing on chromosome 2q is still unknown.
Caspase 8, a member of the mammalian caspase family, has been demonstrated to play a key role in mediating tumor necrosis factor (TNF)-and Fasinduced apoptosis (Boldin et al., 1996; Ceyns and Yuan, 1998) . The formation of the death-inducing signal complex leads to the activation of caspase 8, an initiator of the downstream apoptotic process that induces the activation of caspases 3, 6 and 7 (Salvesen and Dixit, 1997). It was also reported that de®ciency in caspase 8 causes prenatal mortality and a loss of TNFand Fas-induced apoptosis (Yeh et al., 1998; Zhang et al., 1998) . Although caspase 10, homologous to caspase 8, induces apoptosis after transfection into MCF-7 cells, its physiological role is still unknown (FernandesAlnemri et al., 1996; Vincenz and Dixit, 1997) . Recently, the caspase 8 gene was mapped to chromosome 2q33 and caspase 10 found to lie about 40 kb upstream of caspase 8 (Grenet et al., 1999) . More recently, it was reported that the caspase 8 gene was inactivated frequently in NB and its silencing was associated with MYCN ampli®cation (Teitz et al., 2000) . Therefore, to assess whether the inactivation of the caspase 8 and/or 10 plays a role in the pathogenesis of NB and whether another candidate tumor suppressor gene for NB exists on chromosome 2q, we determined the common region of AI on chromosome 2q in 82 primary NBs and further examined the involvement of both the caspase 8 and 10 genes in 27 cell lines and 82 primary tumors of NB.
Results
Frequency and common regions of AI on chromosome 2q in NB Eighty-two cases of NB were examined for AI on chromosome 2q using 10 microsatellite polymorphic markers. The incidence of AI at each locus is summarized in Figure 1 . All cases showed heterozygous genotypes in their normal tissues at one or more loci on chromosome 2q, and AI at one or more loci was detected in 26 of 82 cases (32%). AI on chromosome 2q was schematically summarized in Figure 1 . Eight of 26 cases (31%) showed AI at all informative loci, whereas the other 18 tumors showed partial deletions of chromosome 2q (Figure 1 ). In cases 2, 8, 17, 47 and 78, AI was detected at the D2S116 locus, while heterozygosity was retained at the D2S155 locus. In cases 11 and 62, AI was detected at the D2S116 locus, but heterozygosity was retained at the D2S307 locus. The result from these seven cases indicates the presence of a distinct common region of AI between the D2S115 and D2S307 loci on chromosome 2q33. The distance between these two markers was about 2 cM. Representative autoradiograms of cases 8, 11, 27 and 62 are Figure 2 . Cytogenetic data was obtained in 46 of 82 cases (56%). A review of the association between the modal chromosomal number and AI on chromosome 2q33 was carried out for these cases. Among 12 early stage cases with AI on chromosome 2q33, cytogenetic data was available for nine cases, and three of them were scored as having trisomy of chromosome 2. Moreover, two of 14 advanced stage cases were scored as having both AI and trisomy of chromosome 2. Therefore, AI observed in the tumors was not linked to trisomy of chromosome 2 (data not shown).
Relationship between AI on chromosome 2q33 and clinicopathological findings in NB Since age, stage, and MYCN ampli®cation are known to be associated with the prognosis of patients with NB, the relationship between AI on chromosome 2q33 and these clinicopathological ®ndings was examined.
As shown in Table 1 , there was no signi®cant relationship between AI at 2q33 and any of these parameters by Fisher's exact test. AI at 2q33 was also not associated with the survival of these patients (Table 2, P=0.104).
Expression of the caspase 8 and 10 genes in NB Because both the caspase 8 and 10 genes have been mapped to 2q33 between the D2S115 and D2S307 markers (Grenet et al., 1999) , we examined the expression patterns of these two genes in 27 cell lines and 25 primary tumors of NB by reverse transcription (RT) ± PCR analysis. The caspase 8 gene was reduced or not expressed in 19 of 27 cell lines (70%) and 14 of 25 primary tumors (56%). Among the 19 cell lines, eight cell lines completely lost caspase 8 expression. Caspase 10 expression was not detected in only two of . Recently a caspase 10 long isoform, encoding an insertion of 43 amino acids at the end of the death eector domain, was reported (Wang et al., 1999) . The two isoforms of caspase 10 gene were expressed equally in NB cell lines and primary tumors.
PCR-single-strand conformation polymorphism (SSCP) analysis of the caspase 8 and 10 genes in NB All samples were screened for mutations of the caspase 8 gene by genomic PCR ± SSCP analysis. RT ± PCR ± SSCP analysis was performed for the caspase 10 gene in all NB cell lines and 25 primary tumor samples. Although the SSCP variant of the caspase 10 gene was not detected in the samples examined, an abnormal mobility shift in exon 3 of the caspase 8 gene was observed in one of the cell lines ( Figure 4 ). Sequence analysis of the variant SSCP band revealed a missense mutation at codon 96 from GCT (Alanine) to GTT (Valine). Caspase 8 expression was not detected in this cell line. To examine whether this mutation was a polymorphism or not, we performed PCR ± SSCP analysis of the caspase 8 gene in a total of 95 normal samples. However, we did not detect the same mutation.
Methylation of the caspase 8 gene in NB
Since deletions and mutations of the caspase 8 gene were infrequent in NB, we further investigated whether the caspase 8 gene was transcriptionally silenced in NB cells by methylation of a CpG island in this gene by methylation-speci®c PCR ( Figure 5 ). A methylated fragment of 321 bp was detected in 13 of 19 cell lines (68%) lacking caspase 8 expression and in one cell line with the expression (P=0.031). An unmethylated fragment of 322 bp was detected in all 13 cell lines with caspase 8 expression. Thirteen of the 19 cell lines without caspase 8 expression had the methylated fragment but not the unmethylated fragment, indicating that both alleles of the caspase 8 gene were silenced by methylation in these cell lines. We also examined methylation status in 25 primary NBs. Methylation of the caspase 8 gene was detected in eight of 25 cases (32%). Among 14 cases without caspase 8 expression, hypermethylation was found in seven cases (50%). Only one case showed both methylation and caspase 8 expression.
Relationship of loss of caspase 8 expression to clinical and molecular findings in NB
We next analysed the association of lack of caspase 8 expression and methylation of the caspase 8 gene in NB cell lines. There was a signi®cant correlation To assess the biological signi®cance of the caspase 8 gene in vivo, we further performed statistical analysis in 25 cases of primary NB in which RT ± PCR data of the caspase 8 gene was available. As shown in Table 2 , there was no signi®cant correlation of caspase 8 expression and any clinical parameters, such as age, stage, and result of screening. Six of 14 patients (43%) lacking caspase 8 expression, and three of 11 (27%) patients with caspase 8 expression died within 2 years. Therefore, the ratio of poor survival was slightly higher in the cases without than with caspase 8 expression. However, there was no signi®cant association between lack of caspase 8 expression and survival of the patients with NB (P=0.172). There were signi®cant associations of absent or reduced expression of the caspase 8 gene and both AI at 2q33 and methylation in NBs (P=0.026 and 0.017, respectively (Table 2) .
MYCN ampli®cation was detected in 26 of 27 cell lines (96%) and only three of 25 primary tumors by Southern blot analysis. Therefore, we could not determine correlation of caspase 8 hypermethylation and expression with MYCN ampli®cation in both NB cell lines and primary tumors. It may be due to small number of cell lines without MYCN ampli®cation and primary tumors with MYCN ampli®cation in this study.
Discussion
We demonstrated here the presence of a common region of AI on chromosome 2q and alterations of the caspase 8 gene in NB. A distinct common region of AI in NB was detected at 2q33 between the D2S115 and D2S307 loci. Recently, it has been reported that chromosome 2q was deleted in several types of human cancer, such as lung carcinoma (Shiseki et al., 1994) , head and neck cancer (Ransom et al., 1998) , cervical carcinoma (Mullokandov et al., 1996) , adenocarcinoma of stomach (Nishizuka et al., 1998) and follicular thyroid carcinoma (Tung et al., 1997) . The deleted region in these cancers was mapped to chromosome 2q21-qter and the most frequently deleted region was at chromosome 2q33-qter (Shiseki et al., 1994; Mullokandov et al., 1996; Nishizuka et al., 1998; Ransom et al., 1998) . Furthermore, recently a deletion map of chromosome 2 in lung carcinoma showed the commonly deleted region at 2q32-q37 between the D2S118 and D2S159 markers (Otsuka et al., 1996) . Moreover, homozygous deletion at chromosome 2q33 between the D2S166 and D2S155 markers in a small cell lung carcinoma cell line was also reported . These markers encompassed the common AI region at 2q33 detected in this study. Taken together, it is possible that at least one tumor suppressor gene inactivated in several types of human cancer, including NB, is located at chromosome 2q33.
It was also reported that loss of chromosome 2q was signi®cantly associated with a poor prognosis or advanced stage of the disease in lung cancer, head and neck cancer and follicular thyroid carcinoma (Shiseki et al., 1994; Tung et al., 1997; Ransom et al., 1998) . However, in this study, we did not obtain a correlation between any clinical ®nding and AI at 2q33. Thus, it is likely that the tumor suppressor gene located on chromosome 2q33 in NB plays a dierent role from that of these cancers.
The caspase 8 and 10 genes, both encoding a cystein protease involved in Fas-mediated apoptosis, have been mapped to chromosome 2q33 between the D2S115 and D2S307 loci (Grenet et al., 1999) . More recently, there has been reported homozygous deletion and frequent silencing by methylation, but no mutations of the caspase 8 gene in NB (Teitz et al., 2000) . In this study, we found that caspase 8 expression was frequently reduced or absent in both primary tumors and cell lines of NB. However, we found no homozygous deletions in any cell lines, although one missense mutation was detected in one cell line. This mutation was not observed in 95 normal DNA samples examined. Therefore, the mutation is likely to be a tumor-speci®c mutation rather than a polymorphism. Previously, a mutation at the stop codon which resulted in an increase in the size of the protein encoded by the caspase 8 gene by 88 amino acids was detected in a head and neck carcinoma cell line (Mandruzzato et al., 1997) . To our knowledge, the missense mutation found in this study has not been reported before. This missense mutation was located in the ®rst death eector domain (DED) (Teitz et al., 2000) . We found that caspase 10 expression was lost in only two cell lines (7%) and detected in all primary tumors examined. The two cell lines lacking caspase 10 expression also lost caspase 8 expression. Furthermore, no mutations were detected in either primary tumors or cell lines by RT ± PCR ± SSCP analysis. Thus, these results may suggest that the caspase 10 gene is little involved in the pathogenesis of NB.
DNA methylation of promoter and 5' regulatory sequences may be a pathway for inactivation of several tumor suppressor genes, such as p16, p15 and p73 (Merlo et al., 1995; Herman et al., 1996; Takita et al., 1997 Takita et al., , 1998 . It was also demonstrated that silencing of the caspase 8 gene by methylation occurred preferentially in NB (Teitz et al., 2000) . Thus, we examined the status of the methylation of caspase 8 using a methylation-speci®c PCR. Hypermethylation of the CpG island in the caspase 8 gene was frequently observed in both cell lines and primary tumors lacking caspase 8 expression. This result is similar to that recently reported by Teitz et al. (2000) , who also demonstrated that the caspase 8 gene was re-expressed after 5-aza-deoxycytidine treatment in a subset of NB cell lines with loss of caspase 8 expression and hypermethylation. Therefore, these results suggested that the caspase 8 gene was inactivated mostly by 5' CpG island methylations rather than DNA alterations in NB. There was one cell line showing both methylated and unmethylated fragments, indicating that methylation of this gene may occur heterogeneously in this cell line.
Since loss of caspase 8 expression was signi®cantly correlated with AI on chromosome 2q33 and methylation of the caspase 8 gene, it is likely that AI and methylation would be direct mechanisms for inactivation of the caspase 8 gene in NB. However, we found no relationship between AI at 2q33 and caspase 8 methylation. Thus, the remaining wild type allele is not hypermethylated in the tumors with AI at 2q33. These results indicated that AI combined with methylation might not be a common mechanism for caspase 8 inactivation in NB. Since there were a number of NB tumors lacking caspase 8 expression without AI at 2q33 and/or methylation of the caspase 8 gene, other genetic mechanisms for inactivation of the caspase 8 gene may also function in NB.
There have been several reports that the MYCN gene is involved in apoptosis in NB cells (Lutz et al., 1998; Fulda et al., 1999) . Teitz et al. demonstrated that loss of caspase 8 expression occurred almost exclusively in NB with MYCN ampli®cation (Teitz et al., 2000) . However, in this study, we could not con®rm the correlation between lack of caspase 8 expression and MYCN ampli®cation in the cell lines or primary tumors. This might be due to the small number of cell lines without MYCN ampli®cation and small number of patients examined in this study.
In conclusion, there is a tumor suppressor gene in the common AI region on chromosome 2q33 involved in the pathogenesis of a subset of NB. It is likely that abnormal DNA methylation and AI are important mechanisms for inactivation of the caspase 8 gene in NB. Furthermore, the missense mutation detected in one NB cell line may have some eect on caspase 8 inactivation. Thus, it is possible that the caspase 8 gene is one of the candidate tumor suppressor genes for NB. The pathogenetic signi®-cance of the caspase 8 gene in NB should be investigated further.
Materials and methods

Primary tumor specimens
Eighty-two tumor specimens were randomly obtained at surgery from patients with NB who had been admitted to various institutions between May 1987 and July 1997 . Corresponding normal tissues were available in all cases. Informed consent was obtained from parents of each patient. The patients were staged according to the classi®cation of staging in NB (Evans et al., 1971) . Of the 82 cases, 21 were classi®ed as being stage I, 27 as II, nine as III, 17 as IV and eight as IVS. Seventy-®ve patients were infants under 1 year of age at diagnosis and seven patients were over 1 year old. MYCN ampli®cation was detected in 10 of 82 cases (12%). Since 62 of the 82 cases (76%) were found by a mass screening program, the ratio of infantile and early stage patients in this study was higher than those in previous studies (Fong et al., 1992; Takeda et al., 1994) . Therefore, the population of our cases is extremely biased for low stage disease. However, age, stage and genotype of MYCN were signi®cantly associated with survival of these patients (P50.001). Patients with stages I, II or IVS were treated with either surgery alone or surgery plus chemotherapy mainly consisting of vincristine and cyclophosphamide without radiotherapy. Patients with stage III or IV were treated with multidrug chemotherapy consisting of cyclophosphamide, adriamycin, cisplatin and etoposide with or without surgery, radiotherapy and hematopoietic stem cell transplantation (Sawaguchi et al., 1990; Kaneko et al., 1998) .
Tumor cell lines
We used 27 NB cell lines, NB-1, NB-9, NB-16, NB-19, NB-69, LAN-1, LAN-2, LAN-5, SCMC-N2, SCMC-N3, SCMC-N4, SCMC-N5, SJNB-1, SJNB-2, SJNB-4, TGW, GOTO, NBL, . Four of them (SCMC-N2, SCMC-N3, SCMC-N4 and SCMC-N5) were established in our laboratory (Kong et al., 1997a; Yang et al., 2000) . Six of them (SJNB-1, SJNB-2, SJNB-4, SJNB-5, SJNB-7, SJNB-8) and NBTU1 (Inoue et al., 1997) were a generous gift from Dr AT Look and Dr A Inoue, respectively. The other cell lines were obtained from the Japanese Cancer Resource Cell Bank (http://cellbank.nihs.go.jp/). All cells were maintained in RPMI 1640 (GIBCO ± RLB) medium supplemented with 10% fetal bovine serum in a humidi®ed atmosphere containing 5% CO 2 at 378C.
DNA and total RNA extraction
High molecular weight DNA was isolated from tumors, normal tissues, and cell lines by proteinase K digestion and phenol/chloroform isoamylalcohol (24 : 1) extraction as described previously (Takita et al., 1995) . Total RNA was extracted from the cell lines and tissues using the acid guanidine thiocyanate-phenol chloroform method (Takita et al., 1998) .
PCR ± AI analysis
Ten microsatellite markers used for PCR ± AI analysis are listed in Figure 1 . Total reaction volumes were 10 ml containing 50 ± 100 ng DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 250 mM of each deoxynucleotide triphosphate, 0.01% gelatin, 125 ng of each primer, 1.14 mCi of [a-32 P]dCTP and 1 unit of Taq DNA polymerase (Perkin-Elmer). PCR was performed with Gene Amp PCR system 9700 (Perkin-Elmer) for 35 cycles consisting of denaturation at 958C for 40 s, annealing at 558C for 40 s and extension at 728C for 90 s followed by initial denaturation at 958C for 9 min as described . One-tenth of the PCR product was applied onto 5% urea-formamide-polyacrylamide gels. The gels were dried and exposed to Kodak XAR ®lm for 12 ± 48 h at 7808C.
RT ± PCR analysis
Total RNA from all 27 cell line and 25 primary tumor samples were available for RT ± PCR. Randomly primed cDNA were made from total RNA, reverse transcribed with a cDNA synthesis Kit as previously described (Kong et al., 1997a) . One ml of the cDNA conversion mixture was ampli®ed by PCR in 10 ml of reaction mixture. PCR conditions for the caspase 8 gene were as follows; 30 s at 958C, 30 s at 558C, and 30 s at 728C for 30 cycles, followed by 10 min at 728C. The following primer set was used for RT ± PCR of the caspase 8 gene: CAS8RTS (exon 8), 5'-ACTGTCTGATCATCAACAATCA-3' and CAS8RTA (exon 9), 5'-AACAGGTATACCTTTCTGGT-3'. The primers used for RT ± PCR for the caspase 10 gene were: CASP10-1S, 5'-TGGTGGAGCTTGATCTGAAG-3' and CASP10-1A, 5'-GGTCATTTCAGTTTTGGGAAG-3'; CASP10-2S, 5'-TCT-TCCTTCTGAAAGACTCG-3' and CASP10-2A, 5'-ACT-TCTGCTTCTGCACCAC-3'; CASP10-3S, 5'-CGAAAGTG-GAAATGGAGATG-3' and CASP10-3A, 5'-GTTTGA-GGTCTAAGAACCAA-3'. PCR conditions for the caspase 10 gene were 30 s at 958C, 30 s at 578C and 30 s at 728C for 45 cycles, followed by 10 min at 728C. PCR products were electrophoresed on 2.0% agarose gel and stained with ethidium bromide. The intensity of the caspase 8 expression by RT ± PCR was graded (2+, +, +/7 and 7) in a blinded fashion by two observers (JT and H-WY). Highly abundant expression level (2+) was approximately double that of normal adrenal gland control and reduced expression level (+/7) was approximately one-half of the intensity of normal control (Kong et al., 1997a,b) .
PCR ± SSCP and RT ± PCR ± SSCP analysis
All samples were screened for mutations in the coding region of the caspase 8 gene by genomic PCR ± SSCP analysis. The primer sets used in this study are listed in Table 3 . RT ± PCR ± SSCP was performed for the mutation analysis of the caspase 10 gene in all cell lines and 25 primary tumor samples. Fifty ng of genomic DNA was suspended in 10 ml of PCR buer containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 250 mM of each deoxynucleotide triphosphate, 250 nM of each primer, 1.14 mCi of [a-32 P]dCTP and 1 unit of Taq DNA polymerase (Perkin-Elmer). PCR conditions for the caspase 8 gene were 30 s at 958C, 30 s at 55, 58 or 638C and 30 s at 728C for 35 cycles, followed by 10 min at 728C. PCR conditions for the caspase 10 gene were described in the section on RT ± PCR analysis. The SSCP analysis was performed in a low pH buer system that showed improved separation of long mutant fragments of up to 800 bp (Kukita et al., 1997) . PCR products were denatured and loaded on nondenaturing polyacrylamid gel containing 5% polyacrylamide (99 : 1 acrylamide to bisacrylamide) and TME (30 mM Tris, 35 mM MES {2-[N-Morpholine] ethanesulfonic acid, Dojin Chemicals}, 1 mM Na 2 EDTA, pH 6.8), electrophoresed in TME buer at 258C. Gels were dried and exposed to Kodak XAR ®lms for 12 ± 24 h at 25 or 7808C.
Sequencing analysis
PCR products showing dierent mobilities were puri®ed using SUPREC ± PCR puri®cation kit (Takara) and sequenced directly in both directions with Thermo-Sequence dye terminator cycle sequencing pre-mix kits (Amersham Pharmacia Biotech) and the ABI 310S DNA Sequence System (Perkin-Elmer).
Methylation PCR
Methylation-speci®c PCR was performed in all cell lines and 50 primary tumors as previously described (Teitz et al., 2000) . Primer sets were designed to produce a 321 bp PCR product using methylation primers (sense primer, 5'-TAGGG-GATTCGGACATTGCGA-3' and antisense primer, 5'-CGTATATCTACATTCGAAACGA-3'), and a 322 bp PCR product using unmethylated primers (sense primer, 5'-TAGGGGATTTGGAGATTGTGA-3' and antisense primer, 5'-CCATATATATCTACATTCAAAACAA-3'). After hotstarting at 958C for 5 min, Taq polymerase (Promega) was added and ampli®cation was performed for 35 cycles of 30 s at 958C, 30 s at 648C for the methylated-speci®c primers, or 30 s at 608C for the unmethylated-speci®c primers, followed by 45 s at 728C. Extension was then performed at 728C for 10 min.
Definition of AI
The signal intensity of the polymorphic alleles was quanti®ed and calculated by the scanning densitometer and data analysis system (The Discovery Series TM , Quantity One, pdi, New York, USA). AI was considered to be present if reduction rates of signal intensities in tumors were more than 40% as described previously (Takita et al., 1997) .
Statistical analysis
The signi®cance of the dierences in various biological and clinical features of the disease among the patient group was examined by Fisher's exact test. The vital status of the patients was observed until May 31, 1999. All patients were followed up for at least 15 months and up to 119 months. The survival curves for each group of patients were estimated by the Kaplan ± Meier method, and the resulting curves were compared using the log rank test.
